These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36257986)

  • 1. [Overview of COVID-19 vaccines licensed in the EU-from technology via clinical trial to registration].
    Hildt E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Dec; 65(12):1237-1243. PubMed ID: 36257986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
    Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
    Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tracking the COVID-19 vaccines: The global landscape.
    Yadav T; Kumar S; Mishra G; Saxena SK
    Hum Vaccin Immunother; 2023 Dec; 19(1):2191577. PubMed ID: 36995773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current status of COVID-19 vaccines. A scoping review.
    Rueda-Fernández M; Melguizo-Rodríguez L; Costela-Ruiz VJ; González-Acedo A; Ramos-Torrecillas J; Illescas-Montes R
    Drug Discov Today; 2022 Nov; 27(11):103336. PubMed ID: 35995361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
    Shaw RH; Greenland M; Stuart ASV; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Libri V; Lillie PJ; Morey E; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; White R; Nguyen-Van-Tam JS; Liu X; Snape MD;
    J Infect; 2023 Jun; 86(6):574-583. PubMed ID: 37028454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19: vaccines, efficacy and effects on variants.
    Rudan I; Adeloye D; Sheikh A
    Curr Opin Pulm Med; 2022 May; 28(3):180-191. PubMed ID: 35200162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens.
    Upreti S; Samant M
    Pharm Res; 2022 Sep; 39(9):2119-2134. PubMed ID: 35773445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of COVID-19 Vaccines in SARS-CoV-2 Variants.
    Zhou Z; Zhu Y; Chu M
    Front Immunol; 2022; 13():898192. PubMed ID: 35669787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of SARS-CoV-2 vaccines in patients with cancer.
    Kakkassery H; Carpenter E; Patten PEM; Irshad S
    Trends Mol Med; 2022 Dec; 28(12):1082-1099. PubMed ID: 35999131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Course of 53 Previously Vaccinated Patients Admitted to the National Hospital in Warsaw, Poland with COVID-19 Between November 2021 and March 2022.
    Zaczyński A; Hampel M; Piątkiewicz P; Nasiłowski J; Butkiewicz S; Religioni U; Barańska A; Malm M; Neumann-Podczaska A; Vaillancourt R; Merks P
    Med Sci Monit; 2023 Apr; 29():e939841. PubMed ID: 37118889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological response to vaccines against SARS-CoV-2 in patients with inflammatory bowel disease.
    Algaba A; Romero S; Granja A; Garza D; Aller M; Barrero S; Guerra I; Gil M; Pizarro N; Ruiz P; Prieto S; Hernández B; Pou A; Bermejo F
    Gastroenterol Hepatol; 2023 Jan; 46(1):48-53. PubMed ID: 35605819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines.
    Michalik S; Siegerist F; Palankar R; Franzke K; Schindler M; Reder A; Seifert U; Cammann C; Wesche J; Steil L; Hentschker C; Gesell-Salazar M; Reisinger E; Beer M; Endlich N; Greinacher A; Völker U
    Haematologica; 2022 Apr; 107(4):947-957. PubMed ID: 35045692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions.
    Francis AI; Ghany S; Gilkes T; Umakanthan S
    Postgrad Med J; 2022 May; 98(1159):389-394. PubMed ID: 37066438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of available COVID-19 vaccines in reducing deaths and perspective for next generation vaccines and therapies to counter emerging viral variants: an update.
    Wahid M; Jawed A; Mandal RK; Areeshi MY; El-Shall NA; Mohapatra RK; Tuli HS; Dhama K; Pellicano R; Fagoonee S; Haque S
    Minerva Med; 2023 Oct; 114(5):683-697. PubMed ID: 37293890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis.
    Zeng B; Gao L; Zhou Q; Yu K; Sun F
    BMC Med; 2022 May; 20(1):200. PubMed ID: 35606843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
    Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
    Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
    Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA
    Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines.
    Naranbhai V; Garcia-Beltran WF; Chang CC; Berrios Mairena C; Thierauf JC; Kirkpatrick G; Onozato ML; Cheng J; St Denis KJ; Lam EC; Kaseke C; Tano-Menka R; Yang D; Pavlovic M; Yang W; Kui A; Miller TE; Astudillo MG; Cahill JE; Dighe AS; Gregory DJ; Poznansky MC; Gaiha GD; Balazs AB; Iafrate AJ
    J Infect Dis; 2022 Apr; 225(7):1141-1150. PubMed ID: 34888672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covid-19 vaccines and variants of concern: A review.
    Hadj Hassine I
    Rev Med Virol; 2022 Jul; 32(4):e2313. PubMed ID: 34755408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.